Due to current legislation, Medicare Part D or C plans may only cover Zepbound for obstructive sleep apnea. However, the Centers for Medicare & Medicaid Services may expand weight loss medication ...

Due to current legislation regarding weight loss drugs, Medicare Part D or Part C plans with drug coverage may only cover Zepbound for treating obstructive sleep apnea (OSA). However, the Centers ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

The Centers for Medicare Medicaid Services (CMS) announced it will not proceed with a Biden administration proposal to expand ...

CMS ends Biden-era proposal to expand Medicare coverage of anti-obesity drugs. Seniors continue paying out of pocket for Wegovy and Zepbound ...

Under Friday’s final ruling anti-obesity medications for weight-loss will remain ineligible for Medicare coverage.

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage of anti-obesity drugsThe Trump administration says it will ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...